Skip to main content

Table 1 Clinical characteristics of the patients in the two treatment groups

From: Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial

 

Canagliflozin

Glimepiride

Std diff

Number

113

120

 

Clinical background

 Age, yr

69 ± 9

69 ± 9

0.058

 Male

88 (78)

86 (72)

0.143

 Body mass index kg/m2

25 ± 3

26 ± 4

0.094

 Systolic BP, mmHg

125 ± 14

125 ± 18

0.021

 Heart rate, bpm

75 ± 12

72 ± 13

0.226

Clinical history

 Hypertension

49 (43)

53 (44)

0.016

 Dyslipidemia

46 (41)

54 (45)

0.087

 Myocardial infarction

32 (28)

24 (20)

0.195

 Angina pectoris

24 (21)

27 (23)

0.031

 Coronary artery bypass grafting

12 (11)

11 (9)

0.049

NYHA

 I

72 (64)

76 (63)

0.008

 II

39 (35)

40 (33)

0.025

 III

2 (2)

3 (3)

0.051

 Unknown

0 (0)

1 (1)

0.130

Medications for non-diabetic conditions

 ACEi/ARB

89 (79)

88 (73)

0.127

 Beta blocker

82 (73)

82 (68)

0.093

 MRA

42 (37)

44 (37)

0.010

 Diuretic

46 (41)

53 (44)

0.070

 Statin

87 (77)

86 (72)

0.122

 Anti-platelet or anti-coagulant

71 (63)

66 (55)

0.160

Medication for diabetes

 Insulin

4 (4)

3 (3)

0.061

 Metformin

18 (16)

26 (22)

0.147

 Alpha-glucosidase inhibitor

16 (14)

24 (20)

0.156

 DPP-4 inhibitor

64 (57)

63 (53)

0.083

 GLP-1RA

1 (1)

1 (1)

0.006

Echocardiography

 TMF-E

73.6 ± 25.7

71.9 ± 30.58

0.058

 SEP-e′

6.27 ± 2.87

5.75 ± 2.28

0.199

 E/e′

11.38 ± 5.15

11.59 ± 5.29

0.040

 EF

56.67 ± 14.47

56.64 ± 14.43

0.002

  1. The data are expressed as number of patients (percentage), mean ± SD, or median (interquartile range). A standardized difference (std diff) of < 0.2 indicates adequate balance
  2. Abbreviations: BP, blood pressure; NYHA, New York Heart Association; ACEi/ARB, angiotensin-converting-enzyme inhibitor/angiotensin II receptor blocker; MRA, mineralocorticoid receptor antagonist; DPP-4, dipeptidyl peptidase 4; GLP-1RA, glucagon like peptide-1 receptor agonist. TMF-E, early diastolic transmitral flow; SEP-e′, septal early diastolic mitral annular velocity; EF, ejection fraction